Theravance Biopharma, Inc. Proceeds from Sale of Debt Securities, Available-for-sale
Theravance Biopharma, Inc. (TBPH) reported Proceeds from Sale of Debt Securities, Available-for-sale of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt · last filed 2026-08-11
- Theravance Biopharma, Inc. proceeds from sale of debt securities, available-for-sale for the quarter ending 2026-06-30 was $0.00.
- Theravance Biopharma, Inc. proceeds from sale of debt securities, available-for-sale for the quarter ending 2026-03-31 was $0.00.
- Theravance Biopharma, Inc. proceeds from sale of debt securities, available-for-sale for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- Theravance Biopharma, Inc. proceeds from sale of debt securities, available-for-sale for the quarter ending 2025-09-30 was $0.00.
- Theravance Biopharma, Inc. proceeds from sale of debt securities, available-for-sale for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Theravance Biopharma, Inc. proceeds from sale of debt securities, available-for-sale for fiscal 2024 was $15.80M, a 77.87% decline from fiscal 2023.
- Theravance Biopharma, Inc. proceeds from sale of debt securities, available-for-sale for fiscal 2023 was $71.40M.
- Theravance Biopharma, Inc. proceeds from sale of debt securities, available-for-sale for fiscal 2022 was $0.00.
| Period end | Proceeds from Sale of Debt Securities, Available-for-sale 3 month | Proceeds from Sale of Debt Securities, Available-for-sale 6 month | Proceeds from Sale of Debt Securities, Available-for-sale 9 month | Proceeds from Sale of Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-11 | $0.00 10-Q · filed 2026-08-11 | $0.00 derived: sum of 3 quarters · filed 2026-08-11 | $0.00 derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-07 | $0.00 derived: sum of 2 quarters · filed 2026-05-07 | $0.00 derived: sum of 3 quarters · filed 2026-05-07 | $0.00 derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $0.00 derived: sum of 2 quarters · filed 2026-03-23 | $0.00 derived: sum of 3 quarters · filed 2026-08-11 | $0.00 10-K · filed 2026-03-23 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-12 | $0.00 derived: sum of 2 quarters · filed 2026-08-11 | $0.00 10-Q · filed 2025-11-12 | $15.80M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $0.00 10-Q · filed 2026-08-11 | $0.00 10-Q · filed 2026-08-11 | $15.80M derived: sum of 3 quarters · filed 2026-08-11 | $15.80M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-07 | $15.80M derived: sum of 2 quarters · filed 2026-05-07 | $15.80M derived: sum of 3 quarters · filed 2026-05-07 | $15.80M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $15.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $15.80M derived: sum of 2 quarters · filed 2026-03-23 | $15.80M derived: sum of 3 quarters · filed 2026-03-23 | $15.80M 10-K · filed 2026-03-23 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-12 | $0.00 derived: sum of 2 quarters · filed 2025-11-12 | $0.00 10-Q · filed 2025-11-12 | $0.00 derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-08 | $0.00 10-Q · filed 2024-08-08 | $0.00 derived: sum of 3 quarters · filed 2025-05-12 | $0.00 derived: sum of 4 quarters · filed 2025-05-12 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-12 | $0.00 derived: sum of 2 quarters · filed 2025-05-12 | $0.00 derived: sum of 3 quarters · filed 2025-05-12 | $8.60M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-07 | $0.00 derived: sum of 2 quarters · filed 2025-03-07 | $8.60M derived: sum of 3 quarters · filed 2025-03-07 | $71.40M 10-K · filed 2025-03-07 |
| 2023-09-30 | $0.00 10-Q · filed 2024-11-14 | $8.60M derived: sum of 2 quarters · filed 2024-11-14 | $71.40M 10-Q · filed 2024-11-14 | $71.50M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | $8.60M 10-Q · filed 2024-08-08 | $71.50M 10-Q · filed 2024-08-08 | $71.50M derived: sum of 3 quarters · filed 2024-08-08 | $71.50M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $62.90M 10-Q · filed 2024-05-15 | $62.90M derived: sum of 2 quarters · filed 2024-05-15 | $62.90M derived: sum of 3 quarters · filed 2024-05-15 | $62.90M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $0.00 derived: sum of 2 quarters · filed 2024-03-01 | $0.00 derived: sum of 3 quarters · filed 2024-03-01 | $0.00 10-K · filed 2024-03-01 |
| 2022-09-30 | $0.00 10-Q · filed 2023-11-09 | $0.00 derived: sum of 2 quarters · filed 2023-11-09 | $0.00 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $0.00 10-Q · filed 2023-08-09 | $0.00 10-Q · filed 2023-08-09 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-10 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $0.00 derived: sum of 2 quarters · filed 2023-03-01 | $5.00M derived: sum of 3 quarters · filed 2023-03-01 | $19.90M 10-K · filed 2023-03-01 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $5.00M derived: sum of 2 quarters · filed 2021-11-08 | $19.90M 10-Q · filed 2021-11-08 | $19.90M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $5.00M 10-Q · filed 2021-08-05 | $19.90M 10-Q · filed 2021-08-05 | $19.90M derived: sum of 3 quarters · filed 2022-02-28 | $19.90M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $14.90M 10-Q · filed 2021-05-06 | $14.90M derived: sum of 2 quarters · filed 2022-02-28 | $14.90M derived: sum of 3 quarters · filed 2022-02-28 | $14.90M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $0.00 derived: sum of 2 quarters · filed 2022-02-28 | $0.00 derived: sum of 3 quarters · filed 2022-02-28 | $0.00 10-K · filed 2022-02-28 |
| 2019-09-30 | $0.00 10-Q · filed 2020-05-08 | $0.00 derived: sum of 2 quarters · filed 2020-08-10 | $0.00 10-Q · filed 2020-05-08 | $0.00 derived: sum of 4 quarters · filed 2020-08-10 |
| 2019-06-30 | $0.00 10-Q · filed 2020-08-10 | $0.00 10-Q · filed 2020-08-10 | $0.00 derived: sum of 3 quarters · filed 2020-08-10 | $0.00 derived: sum of 4 quarters · filed 2020-08-10 |
| 2019-03-31 | $0.00 10-Q · filed 2019-05-10 | $0.00 derived: sum of 2 quarters · filed 2019-05-10 | $0.00 derived: sum of 3 quarters · filed 2020-05-08 | $0.00 derived: sum of 4 quarters · filed 2020-05-08 |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $0.00 derived: sum of 2 quarters · filed 2020-05-08 | $0.00 derived: sum of 3 quarters · filed 2020-05-08 | $0.00 10-K · filed 2019-02-28 |
| 2018-09-30 | $0.00 10-Q · filed 2020-05-08 | $0.00 derived: sum of 2 quarters · filed 2020-05-08 | $0.00 10-Q · filed 2020-05-08 | |
| 2018-06-30 | $0.00 10-Q · filed 2019-08-05 | $0.00 10-Q · filed 2019-08-05 | ||
| 2018-03-31 | $0.00 10-Q · filed 2019-05-10 | |||
| 2017-12-31 | $0.00 10-K · filed 2019-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |